摘要
目的探讨肺泡表面活性物质制剂固尔苏预防早产儿呼吸窘迫综合征的临床疗效。方法将胎龄≤32周,体重≤1 500 g的早产儿36例分两组进行前瞻性临床研究,观察组18例出生后2 h内气管内滴入固尔苏,对照组18例未应用固尔苏。结果观察组发生新生儿呼吸窘迫综合征、出现并发症及死亡的例数较对照组明显减少(P<0.05);出生后6 h血气分析结果显示,观察组显著优于对照组(P<0.01)。结论早产儿生后应尽早预防性应用固尔苏,可显著降低新生儿呼吸窘迫综合征的发病率,减少呼吸机的应用,提高早产儿的存活率。
Objective To evaluate the clinical effect of pulmonary surfactant Curosurf in preventing respiratory distress syndrome of prematures. Methods Thirty-six preterm infants with gestational age of 28 - 32 weeks and birth weight of 1 180 - 1 500 g were randomly divided into two groups . Among them, 18 neonates of treated group were dripped in Curosurf through trachea within two hour after birth and 18 neonates served as control. Results The incidences of NRDS , complications and mortality in treated group were obviously lower than those in control group （P〈0.05） . The results of blood gas analysis within six hours after birth showed that the treated group were much better than the control group（P〈0,01）. Conclusion The preventive application of Curosurf early for prematures can remarkably reduce the rate of NRDS and mechanical ventilation dependence, and increase the survival rate.
出处
《同济大学学报（医学版）》
CAS
2007年第5期72-74,77,共4页
Journal of Tongji University(Medical Science)
